$40.00
In stock
ARA-290 is an 11-amino acid peptide derived from the helix B surface domain of erythropoietin (EPO), engineered to selectively interact with the innate repair receptor (IRR), a heteromeric complex comprising the EPO receptor and the β-common receptor (CD131), without engaging the EPO receptor homodimer responsible for erythropoiesis.
Store in a cool, dark place or freeze at -20°C for long term storage. Refrigerate after reconstitution
Name: ARA-290
CAS Number: 1208243-50-8
Molecular Formula: C₅₁H₈₄N₁₆O₂₁
Molecular Mass (monoisotopic/average): 1257.3 g/mol
PubChem ID (CID): 91810664
ARA-290 (also known as Cibinetide, PHBSP, or pyroglutamate helix B surface peptide) is a synthetic undecapeptide (11 amino acids long) engineered as a non-erythropoietic analogue derived from the helix B surface region of erythropoietin (EPO), featuring an N-terminal pyroglutamic acid (Pyr or pGlu) residue for stability and a linear sequence without cyclic structures, disulfide bridges, or other post-translational modifications beyond the pyroglutamyl cyclization.
Its amino acid sequence is: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (or {Glp}-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; single-letter code: pGlu-EQ L E R A L N S S, with free C-terminus).
Chemically, it has the molecular formula C₅₁H₈₄N₁₆O₂₁ and a molar mass of approximately 1257.3 g/mol (CAS 1208243-50-8). This oligopeptide is classified as a research chemical and is commonly utilized in laboratory investigations of peptide-receptor interactions
All items available on this website are intended exclusively for research and development purposes, including laboratory and analytical applications, and are not meant for human or animal consumption in any form. The products are not designed to diagnose, treat, cure, or prevent any medical conditions, and their associated claims have not been reviewed or approved by the U.S. Food and Drug Administration. Purus Peptides operates solely as a supplier of research chemicals and is neither a compounding pharmacy nor an outsourcing facility as defined by sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act
